LOS ANGELES, CA / ACCESSWIRE / July 25, 2016 / Lundin Law PC (the “Firm”) announces that a class action lawsuit was filed against Halyard Health, Inc. (“Halyard” or the “Company”) (NYSE: HYH) on behalf of investors who purchased or otherwise acquired shares (1) on or after February 25, 2013 and subsequently received Halyard securities pursuant to the spin-off of Kimberly-Clark Corporation (NYSE: KMB) from Halyard, effective as of October 31, 2014; and/or (2) purchased or otherwise acquired Halyard securities between October 21, 2014 and April 29, 2016, both dates inclusive (collectively, the “Class Period”), seeking to recover damages caused by the Company’s violations of the federal securities laws.

Investors who purchased or otherwise acquired shares during one of those periods should contact the Firm in advance of the August 29, 2016 lead plaintiff
motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that the Company issued misleading statements and/or failed to disclose that: the Company’s MICROCOOL surgical gowns consistently failed effectiveness tests and failed to meet industry standards; and Kimberly-Clark and Halyard had knowingly provided defective MICROCOOL surgical gowns to U.S. workers during the Ebola crisis. When this news was announced, shares of Halyard stock dropped in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442815

IRVINE, CA / ACCESSWIRE / July 25, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against Juno Therapeutics Inc. (“Juno” or the “Company”) (NASDAQ: JUNO). Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the
September 12, 2016 lead plaintiff motion deadline.

If you purchased shares of Juno during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that, during the Class Period, Juno failed to disclose that a patient died during a clinical trial for its product candidate in May 2016. Juno was thus trading at artificially inflated prices and some insiders participated in heavy selling of shares until July 7, 2016. On July 7, 2016 the Company announced the May 2016 death and two additional deaths during clinical trial, and the Food and Drug Administration put a hold on the trial. After the release of this news, shares of Juno fell in value.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442814

FORT MYERS, FL / ACCESSWIRE / July 25, 2016 / NeoGenomics, Inc. (NASDAQ: NEO) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Tuesday, July 26, 2016 at 11:00 AM Eastern Time.

To participate in this event, dial 877-407-8035 domestically, or 201-689-8035 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=175124 as well as via the NeoGenomics website (www.neogenomics.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.neogenomics.com.

You may access the teleconference replay by dialing 877-481-4010 domestically or 919-882-2331 internationally, referencing conference ID # 10043. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 9, 2016.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for Physicians to help them diagnose and treat cancer. The Company’s BioPharma division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.com.

SOURCE: Investor Calendar

ReleaseID: 442812

SUNNYVALE, CA / ACCESSWIRE / July 25, 2016 / Juniper Networks (NYSE: JNPR) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Tuesday, July 26, 2016 at 5:00 PM Eastern Time.

To participate in this event, dial 877-407-8033 domestically, or 201-689-8033 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at the Juniper Networks website (investor.juniper.net).

About Juniper Networks

Juniper Networks (JNPR) challenges the status quo with innovative hardware, software and services critical to business transformation in the connected world. We are a leader in network automation, performance and collaboration. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter and Facebook.

SOURCE: Investor Calendar

ReleaseID: 442811

CHATTANOOGA, TN / ACCESSWIRE / July 25, 2016 / Astec Industries, Inc. (NASDAQ: ASTE) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Tuesday, July 26, 2016 at 10:00 AM Eastern Time.

To participate in this event, dial 877-407-9210 domestically, or 201-689-8049 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=175169 as well as via the Astec Industries, Inc. website (www.astecindustries.com/conferencecalls).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.astecindustries.com.

You may access the teleconference replay by dialing 877-481-4010 domestically or 919-882-2331 internationally, referencing conference ID # 10057. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 9, 2016.

About Astec Industries, Inc.

Astec Industries, Inc. (www.astecindustries.com), is a manufacturer of specialized equipment for asphalt road building; aggregate processing; wood processing and water well, oil and gas drilling. Astec’s manufacturing operations are divided into three primary business segments: road building and related equipment (Infrastructure Group); aggregate processing and mining equipment (Aggregate and Mining Group); and equipment for the extraction and production of fuels, biomass production, and water drilling equipment (Energy Group).

SOURCE: Investor Calendar

ReleaseID: 442809

NEW YORK, NY / ACCESSWIRE / July 25, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased National Interstate Corporation (“National Interstate”) (NASDAQ: NATL) stock prior to July 25, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of National Interstate Corporation to Great American Insurance Company, a subsidiary of American Financial Group, Inc. for $32.00 per share. Great American Insurance Company currently owns approximately 51% of the company’s outstanding shares. To learn more about the action and your rights, go to: http://zlk.9nl.com/national-interstate or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 442810

TORONTO, ON / ACCESSWIRE / July 25, 2016 / Cava Resources Inc. (TSXV: CVA) (“Cava” or, the “Company”) announces that the Company has completed a private placement financing of 750,000 units at an issue price of $0.20 per unit for gross proceeds of $150,000. Each unit is comprised of one common share and one-half of one common share purchase warrant, with each whole warrant exercisable into a common share at an exercise price of $0.40 per share for a period of 24 months.

Proceeds from the financing will be used to advance the Company’s Casa Berardi property, to evaluate other resource property opportunities and for general corporate purposes.

All securities issued in connection with the private placement are subject to a hold period of four months and a day. The private placement is subject to final approval of the TSX Venture Exchange.

For further information contact:

R. Brian Murray,
President, 416-985-7810

John V. Hickey,
CFO, 416-903-6649

The TSXV has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release. The TSXV has neither approved nor disapproved the contents of this news release.

All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding potential mineralization and reserves, exploration results, and future plans and objectives of the Company, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are exploration risks detailed herein and from time to time in the filings made by the Company with securities regulators.

SOURCE: Cava Resources Inc.

ReleaseID: 442806

IRVINE, CA / ACCESSWIRE / July 25, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ: CHMA). Investors who purchased or otherwise acquired shares between July 15, 2015 and April 17, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August
8, 2016, lead plaintiff motion deadline.

If you purchased shares of Chiasma during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that the Company made materially false and/or misleading statements about its business during the Class Period. The Company failed to disclose that the Phase 3 clinical trial for its oral octreotide, Mycapssa, which was conducted before the July 15, 2015 IPO, was insufficient to prove efficacy and secure FDA approval. Also Chiasma’s supervision of its suppliers was not sufficient to prevent deficiencies that delayed FDA approval of Mycapssa. On April 18, 2016 the Company announced that the FDA issued a Complete Response Letter in response to the Company’s New Drug Application for Mycapssa, stating that the FDA did not believe the application provided sufficient evidence of efficacy to warrant approval and another clinical trial would be necessary, and that deficiencies with the Company’s suppliers would need to be resolved. When Chiasma announced this news on April 18, 2016, the share price fell 63.13% on that day.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442805

NEW YORK, NY / ACCESSWIRE / July 25, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Yadkin Financial Corporation (“Yadkin”) (NYSE: YDKN) stock prior to July 21, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Yadkin to F.N.B. Corporation (NYSE: FNB) for 2.16 shares of FNB common stock per Yadkin share, representing an approximate value of $27.35 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/yadkin-financial-ydkn or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 442807

LOS ANGELES, CA / ACCESSWIRE / July 25, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead
plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that the Company made misrepresentations about the FDA approval process for its new anticoagulant drug, KANGIO™. Specifically, on February 25, 2016, the Company’s CEO stated, regarding the pending New Drug Application (“NDA”) for KANGIO™, “We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.” On March 18, 2016 Eagle disclosed that the FDA did not approve the NDA because it required further information about the substances used in KANGIO™. When this news was announced, shares of Eagle fell in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442804